Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the…
Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about…
SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line…
A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.
AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms…
Applying the Dogs of the Dow logic across the entire S&P 500 sounds like a recipe for chasing troubled dividends, but a holding-by-holding look at SDOG reveals a more complicated picture, with…
Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying…
SCHD's 100-stock structure and rock-bottom fees make it a retiree favorite, but a closer look at its top four holdings reveals one company sitting on a patent cliff that could quietly reshape…
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may…
Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether…
Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question…
Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping…
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a…
